Your browser doesn't support javascript.
loading
Selection process and causes of non-eligibility for CD19 CAR-T cell therapy in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma in a European center.
Carpio, Cecilia; Iacoboni, Gloria; Villacampa, Guillermo; Catalá, Eva; Bobillo, Sabela; Pérez, Ana; Jiménez, Moraima; Segura, Laura; Olivé, Mireia; Farriols, Anna; Abrisqueta, Pau; Valcárcel, David; Carreras, María Josep; Bosch, Francesc; Barba, Pere.
Afiliação
  • Carpio C; Department of Hematology, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital (HUVH), Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Iacoboni G; Department of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Villacampa G; Department of Hematology, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital (HUVH), Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Catalá E; Department of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Bobillo S; Oncology Data Science (OdysSey) Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Pérez A; Department of Hematology, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital (HUVH), Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Jiménez M; Department of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Segura L; Department of Hematology, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital (HUVH), Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Olivé M; Department of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Farriols A; Department of Hematology, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital (HUVH), Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Abrisqueta P; Department of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Valcárcel D; Department of Hematology, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital (HUVH), Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Carreras MJ; Department of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Bosch F; Department of Hematology, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital (HUVH), Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Barba P; Department of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain.
Leuk Lymphoma ; 62(9): 2288-2291, 2021 09.
Article em En | MEDLINE | ID: mdl-33899648
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Linfoma de Células B / Receptores de Antígenos Quiméricos Tipo de estudo: Etiology_studies Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Linfoma de Células B / Receptores de Antígenos Quiméricos Tipo de estudo: Etiology_studies Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article